The European Medicines Agency (EMA) has recommended that marketing authorisation for Tavneos (avacopan) be revoked due to a question mark over the integrity of clinical data used to support its ...

Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce.

Sobi has received a CRL from the US FDA regarding its BLA for NASP, an investigational therapy intended for adults with uncontrolled gout.

Lilly has received the CHMP of the EMA positive opinion for Jaypirca (pirtobrutinib) to treat chronic lymphocytic leukaemia (CLL) in adults.

Earlier this year, Ionis’ CEO Brett Monia said that Tryngolza (olezarsen) would become the company’s first fully owned blockbuster drug, with that forecast having just become ...

Immunai and Boehringer Ingelheim have entered into a multi-project collaboration to identify new T-cell targets in oncology and autoimmune diseases.

Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201, leaving the biopharma company po ...

Ionis Pharmaceuticals has granted Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.

Former FDA employees discussed whether the agency’s commitment to openness risks creating a lack of clarity on official policies.

The EC has approved MSD's Keytruda in combination with Padcev as a neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).

RQ Bio has closed a $115m Series A funding round to advance its long-acting antibody therapeutic programme RQB01, which targets influenza prevention in high-risk and immunocompromised groups.

Active job postings in healthtech have fallen consistently, with a decline of more than 40%. This is not seasonal noise.